Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Atrial Fibrillation-Pipeline Review, H1 2015

Atrial Fibrillation-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Atrial Fibrillation-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Atrial Fibrillation-Pipeline Review, H1 2015', provides an overview of the Atrial Fibrillation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Atrial Fibrillation Overview 9

Therapeutics Development 10

Pipeline Products for Atrial Fibrillation-Overview 10

Pipeline Products for Atrial Fibrillation-Comparative Analysis 11

Atrial Fibrillation-Therapeutics under Development by Companies 12

Atrial Fibrillation-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Atrial Fibrillation-Products under Development by Companies 17

Atrial Fibrillation-Companies Involved in Therapeutics Development 19

ARCA biopharma, Inc. 19

Armetheon, Inc. 20

AstraZeneca PLC 21

Bristol-Myers Squibb Company 22

Cardiome Pharma Corp 23

Daiichi Sankyo Company, Limited 24

Gilead Sciences, Inc. 25

Isis Pharmaceuticals, Inc. 26

Laboratoires Pierre Fabre SA 27

Nissan Chemical Industries, Ltd. 28

Nyken BV 29

Otsuka Holdings Co., Ltd. 30

Regado Biosciences, Inc. 31

Serodus ASA 32

Xention Limited 33

Atrial Fibrillation-Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Combination Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

(ranolazine + dronedarone)-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Aptamers for Cardiovascular Diseases-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

BMS-919373-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

bucindolol hydrochloride-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

budiodarone-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Drug For Atrial Fibrillation-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

edoxaban tosylate-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

F-373280-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

GsMTx-4-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ISIS-CRPRx-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

NIP-151-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

NYK-1112-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

OMT-33-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

OPC-108459-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

ranolazine ER-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

SER-102-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecule to Block IKACh for Atrial Fibrillation-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Small Molecule to Block Kv1.5 for Atrial Fibrillation-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecules to Activate Heat Shock Protein 70 (Hsp70) for Post-Operative Atrial Fibrillation-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

vanoxerine-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

vernakalant hydrochloride-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

XEN-D0101-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

XEN-D0103-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

XEN-R0702-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Atrial Fibrillation-Recent Pipeline Updates 78

Atrial Fibrillation-Dormant Projects 90

Atrial Fibrillation-Discontinued Products 94

Atrial Fibrillation-Product Development Milestones 95

Featured News & Press Releases 95

Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 95

Nov 07, 2014: Cardiome Announces Positive Results from the BRINAVESS Asia-Pacific Phase 3 Clinical Trial 95

Nov 07, 2014: Cardiome Submits BRINAVESS Reimbursement Dossier to Italian Authorities to Support Market Access 96

Oct 31, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA (edoxaban) for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 96

Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 97

Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 98

Sep 02, 2014: Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes 98

Sep 01, 2014: Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation 100

Aug 25, 2014: Cardiome Enters Commercialization Agreement With Eurolab Especialidades Medicinales For BRINAVESS In Argentina 101

Aug 06, 2014: Cardiome Submits Brinavess Dossier To French Authorities To Support Market Access 101

Appendix 102

Methodology 102

Coverage 102

Secondary Research 102

Primary Research 102

Expert Panel Validation 102

Contact Us 103

Disclaimer 103

List of Tables

Number of Products under Development for Atrial Fibrillation, H1 2015 10

Number of Products under Development for Atrial Fibrillation-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Atrial Fibrillation-Pipeline by ARCA biopharma, Inc., H1 2015 19

Atrial Fibrillation-Pipeline by Armetheon, Inc., H1 2015 20

Atrial Fibrillation-Pipeline by AstraZeneca PLC, H1 2015 21

Atrial Fibrillation-Pipeline by Bristol-Myers Squibb Company, H1 2015 22

Atrial Fibrillation-Pipeline by Cardiome Pharma Corp, H1 2015 23

Atrial Fibrillation-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 24

Atrial Fibrillation-Pipeline by Gilead Sciences, Inc., H1 2015 25

Atrial Fibrillation-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 26

Atrial Fibrillation-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 27

Atrial Fibrillation-Pipeline by Nissan Chemical Industries, Ltd., H1 2015 28

Atrial Fibrillation-Pipeline by Nyken BV, H1 2015 29

Atrial Fibrillation-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 30

Atrial Fibrillation-Pipeline by Regado Biosciences, Inc., H1 2015 31

Atrial Fibrillation-Pipeline by Serodus ASA, H1 2015 32

Atrial Fibrillation-Pipeline by Xention Limited, H1 2015 33

Assessment by Monotherapy Products, H1 2015 34

Assessment by Combination Products, H1 2015 35

Number of Products by Stage and Target, H1 2015 37

Number of Products by Stage and Mechanism of Action, H1 2015 39

Number of Products by Stage and Route of Administration, H1 2015 41

Number of Products by Stage and Molecule Type, H1 2015 43

Atrial Fibrillation Therapeutics-Recent Pipeline Updates, H1 2015 78

Atrial Fibrillation-Dormant Projects, H1 2015 90

Atrial Fibrillation-Dormant Projects (Contd..1), H1 2015 91

Atrial Fibrillation-Dormant Projects (Contd..2), H1 2015 92

Atrial Fibrillation-Dormant Projects (Contd..3), H1 2015 93

Atrial Fibrillation-Discontinued Products, H1 2015 94

List of Figures

Number of Products under Development for Atrial Fibrillation, H1 2015 10

Number of Products under Development for Atrial Fibrillation-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 34

Number of Products by Top 10 Targets, H1 2015 36

Number of Products by Stage and Top 10 Targets, H1 2015 36

Number of Products by Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Top 10 Routes of Administration, H1 2015 40

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 41

Number of Products by Top 10 Molecule Types, H1 2015 42

Number of Products by Stage and Top 10 Molecule Types, H1 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ARCA biopharma, Inc.

Armetheon, Inc.

AstraZeneca PLC

Bristol-Myers Squibb Company

Cardiome Pharma Corp

Daiichi Sankyo Company, Limited

Gilead Sciences, Inc.

Isis Pharmaceuticals, Inc.

Laboratoires Pierre Fabre SA

Nissan Chemical Industries, Ltd.

Nyken BV

Otsuka Holdings Co., Ltd.

Regado Biosciences, Inc.

Serodus ASA

Xention Limited

Atrial Fibrillation Therapeutic Products under Development, Key Players in Atrial Fibrillation Therapeutics, Atrial Fibrillation Pipeline Overview, Atrial Fibrillation Pipeline, Atrial Fibrillation Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com